<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">clinvest</journal-id><journal-title-group><journal-title xml:lang="ru">Качественная клиническая практика</journal-title><trans-title-group xml:lang="en"><trans-title>Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2588-0519</issn><issn pub-type="epub">2618-8473</issn><publisher><publisher-name>ООО «Издательство ОКИ</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">clinvest-66</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL TRIALS</subject></subj-group></article-categories><title-group><article-title>Роль провизора в команде исследовательского центра ранних фаз</article-title><trans-title-group xml:lang="en"><trans-title>The role of pharmacist in early phase clinical research</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Возжаев</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vozzhaev</surname><given-names>A. V.</given-names></name></name-alternatives><email xlink:type="simple">alex.vozzhaev@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фитилёв</surname><given-names>С. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Fitilev</surname><given-names>S. B.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Якушев</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakushev</surname><given-names>V. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шкребнёва</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Shkrebneva</surname><given-names>I. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский университет дружбы народов», г. Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Peoples' Friendship University of Russia, Moscow, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАО УВО «Российский университет дружбы народов»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Peoples' Friendship University of Russia, Moscow, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГАО УВО «Российский университет дружбы народов»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>FGAOU VO «RUDN University»</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>16</day><month>05</month><year>2018</year></pub-date><volume>0</volume><issue>4</issue><fpage>39</fpage><lpage>42</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Возжаев А.В., Фитилёв С.Б., Якушев В.А., Шкребнёва И.И., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Возжаев А.В., Фитилёв С.Б., Якушев В.А., Шкребнёва И.И.</copyright-holder><copyright-holder xml:lang="en">Vozzhaev A.V., Fitilev S.B., Yakushev V.A., Shkrebneva I.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.clinvest.ru/jour/article/view/66">https://www.clinvest.ru/jour/article/view/66</self-uri><abstract><p>В данной статье обсуждается роль специалиста-провизора в практической деятельности исследовательского коллектива при проведении клинических исследований ранних фаз. Авторы подчеркивают, что отчасти в силу недостатка нормативной документации, регулирующей данную отрасль в нашей стране, такие специалисты редко привлекаются к работе отделений I фазы. Анализ опыта зарубежных коллег показывает обратную картину - фармацевтическое звено является неотъемлемой частью в большинстве клинических центров. Особую актуальность данная проблема приобретает в свете неуклонного роста количества исследований ранних фаз в России за последние несколько лет. Основываясь на собственном практическом опыте, авторы описывают основные функциональные обязанности провизора как члена команды исследователей центра ранних фаз, отдельно останавливаясь на квалификационных требованиях, которым должен соответствовать такой специалист. С учётом роста не только количества исследований, но и отделений I фазы, в том числе на базе частных клиник, ценность провизоров-исследователей будет также повышаться.</p></abstract><trans-abstract xml:lang="en"><p>This article discusses the role of pharmacist in early phase clinical trials. Authors emphasize that in Russian phase I units pharmacists are rarely involved in clinical research activities. Probably the lack of regulatory documentation in this field is one of the main reasons. The opposite situation occurs abroad where pharmacist is key member of investigational team. This problem is particularly relevant because number of phase I studies in Russia steadily increases over the last years. Based on their practical experience authors describe the range of pharmacist functions and responsibilities when working in early phase research. Qualification requirements and skills of such specialist are pointed out as well. Due to the fact that not only number of trials but also number of phase I units increases (including private departments) the value of pharmacist in clinical research will grow.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>клинические исследования</kwd><kwd>отделение I фазы</kwd><kwd>роль провизора</kwd><kwd>исследуемый препарат</kwd><kwd>clinical trial</kwd><kwd>phase I unit</kwd><kwd>role of pharmacist</kwd><kwd>investigational product</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Федеральный государственный образовательный стандарт высшего образования по специальности 33.05.01 Фармация (уровень специалитета) (утв. приказом Министерства образования и науки РФ от 11 августа 2016 г. №1037).</mixed-citation><mixed-citation xml:lang="en">Федеральный государственный образовательный стандарт высшего образования по специальности 33.05.01 Фармация (уровень специалитета) (утв. приказом Министерства образования и науки РФ от 11 августа 2016 г. №1037).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">American Society of Health-System Pharmacists. ASHP guidelines on clinical drug research. Am J Health-Syst Pharm. 1998 (revised on 2003); 55:369-76.</mixed-citation><mixed-citation xml:lang="en">American Society of Health-System Pharmacists. ASHP guidelines on clinical drug research. Am J Health-Syst Pharm. 1998 (revised on 2003); 55:369-76.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Professional guidance on pharmacy services for clinical trials, 2013, NPCTAG.</mixed-citation><mixed-citation xml:lang="en">Professional guidance on pharmacy services for clinical trials, 2013, NPCTAG.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Guidelines for phase 1 clinical trials, 2012 edition, ABPI.</mixed-citation><mixed-citation xml:lang="en">Guidelines for phase 1 clinical trials, 2012 edition, ABPI.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">First in Human Studies, 2011, ABPI.</mixed-citation><mixed-citation xml:lang="en">First in Human Studies, 2011, ABPI.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">dinical Trials in Russia. Orange Paper, Annual 2016. CRO Synergy Research Group, 2016. - 13 pp.</mixed-citation><mixed-citation xml:lang="en">dinical Trials in Russia. Orange Paper, Annual 2016. CRO Synergy Research Group, 2016. - 13 pp.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">dinical Trials in Russia. Orange Paper, Annual 2015. CRO Synergy Research Group, 2015. - 13 pp.</mixed-citation><mixed-citation xml:lang="en">dinical Trials in Russia. Orange Paper, Annual 2015. CRO Synergy Research Group, 2015. - 13 pp.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
